As plasmablasts originate from non-IgE memory cells, it has been speculated that dupilumab resulted in a marked reduction of serum allergen-specific IgE -an IL-4 and IL-13-dependent process- as a large portion of circulating IgE in AD patients derives from short-lived IgE plasma cells elicited in recent class-switching events (25). This evidence concerns the gene IGHE and Alzheimer disease.